Want to see RDHL full AI Analyst Report?
RDHL Stock Chart & Stats
$1.20
-$0.32(-4.91%)
At close: 4:00 PM EST
$1.20
-$0.32(-4.91%)
Day’s Range― - ―
52-Week Range$0.44 - $1.90
Previous CloseN/A
Volume5.64K
Average Volume (3M)679.76K
Market Cap
$4.45M
Enterprise Value$1.05M
Total Cash (Recent Filing)$2.87M
Total Debt (Recent Filing)$214.00K
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Mar 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding8,887,684
10 Day Avg. Volume1,669,906
30 Day Avg. Volume679,765
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market Cap0.24
Enterprise Value/Revenue0.11
Enterprise Value/Gross Profit0.17
Enterprise Value/Ebitda-0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$50.60M
Bulls Say, Bears Say
Bulls Say
Focused GI Commercial PortfolioThe portfolio reset gives RedHill control of two established, FDA-approved GI products with demonstrated commercial demand. Rebyota and Clenpiq provide a larger operating platform than the prior business and could support more durable revenue generation as commercialization expands.
Improved Liquidity And EquityThe Talicia divestiture supplied upfront cash that funded the new GI rights while preserving potential milestone upside. Reported positive equity and strengthened liquidity improve financial flexibility, helping RedHill support commercialization and pursue its revised strategy.
Pipeline And Regulatory OptionalityThe development pipeline adds potential value beyond the commercial portfolio. FDA rare pediatric disease designation may create future regulatory benefits for opaganib, while RHB-204’s Phase 2-ready positioning could broaden RedHill’s GI opportunity if subsequent clinical development succeeds.
Bears Say
Severe Revenue ContractionThe sharp top-line decline indicates that prior commercial revenue was not durable and leaves the company with a much smaller base from which to rebuild. Persistent operating losses also show that the current business has not yet achieved sustainable earnings power.
Persistent Cash BurnContinued operating and free-cash-flow deficits mean RedHill is consuming substantial cash while it develops and commercializes its revised portfolio. This weak internal funding capacity can constrain investment and maintain dependence on financing or asset sales.
Reliance On Equity FinancingExpanding the ATM offering signals that external equity remains an important funding tool for the company. Repeated reliance on ADS issuance can dilute existing shareholders and reflects the challenge of financing operations while cash generation remains negative.
RedHill Biopharma News
RDHL FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $0.43 and its highest was $1.90 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is $4.45M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Mar 18, 2027 which is in 148 days.
How were RedHill Biopharma’s earnings last quarter?
RedHill Biopharma released its earnings results on Sep 30, 2026. The company reported -$1.007 earnings per share for the quarter.
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 8,887,684 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
RedHill Biopharma reported an EPS of -$1.007 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in RDHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Technical Analysis
Ironwood Pharma
―
Perrigo Company
―
SIGA Technologies
―
Teva
―
Takeda Pharmaceutical Company
―
Ownership Overview
― Insiders
―
Mutual Funds
9.25% Other Institutional Investors
90.75% Public Companies and
Individual Investors